<DOC>
	<DOCNO>NCT01868646</DOCNO>
	<brief_summary>The purpose study : - ass clinical efficiency Subetta combine treatment type II diabetes mellitus ; - ass safety Subetta combine treatment type II diabetes mellitus .</brief_summary>
	<brief_title>Clinical Trial Efficiency Safety Subetta Combined Treatment Patients With Type II Diabetes Mellitus</brief_title>
	<detailed_description>Patients type II diabetes mellitus include trial . It concern patient , time trial receive basal insulin metformin metformin sulfonylurea derivative lack optimal glycemic control ( HbA1c &gt; 7.0 % ) . For patient , include trial ( mainly middle age patient without severe complication diabetes ) , HbA1c &gt; 7.0 % marker show optimal individual goal glycemic control achieve . If patient meet inclusion criterion show non- inclusion criterion he/she randomize one 2 group : Group 1 - group receive standard type II diabetes mellitus therapy + Subetta dose 1 tablet 4 time day ; Group 2 - group receive standard type II diabetes mellitus therapy + Placebo regimen use Subetta . The invented name drug contain basal insulin , metformin sulfonylurea derivative use standard type II diabetes mellitus therapy , unchanged patient whole trial . All patient receive glucometers appropriate glucose test strip , could self monitor blood glucose register data diary . The trial duration 38 week ; main stage trial conduct screening , 4 week ( Visit 2 ) , 12 week ( Visit 3 ) , 24 week ( Visit 4 ) 36 week ( Visit 5 ) . In 1 week randomization onset trial therapy visit study site ( week 8±1 , 18±1and 30±1 ) investigator collect data patient 's health complaint ( phone visit ) decide whether necessary arrange unplanned visit site .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Diagnosed type II diabetes mellitus ( accord WHO criterion , 1999 2006 ) . 2 . Patient 's age 18 65 year inclusive . 3 . Level glycosylated hemoglobin 7.0 10.0 % . 4 . Dose basal insulin ≥10 units/day combine metformin metformin sulfonylurea derivative less 3 month prior inclusion trial . 5 . Body build index ≥25.0 ≤40.0kg/m^2 . 6 . Constant body weight ( without fluctuation &gt; 10 % less 3 month prior inclusion trial ) . 7 . Glomerular filtration rate ≥ 60 ml/ min/1.73m^2 . 8 . Stable dose basal insulin last 3 month . ( Permissible fluctuation ±10 % . ) 9 . Usage contraceptive method gender patient reproductive age trial within 30 day end participation trial . 10 . Availability sign patient information sheet ( Informed Consent form ) participation clinical trial . 1 . Acute diabetes mellitus complication 3 month prior inclusion trial ( diabetic ketoacidosis , hyperosmolar hyperglycemic state , lacticemia , severe hypoglycemia hypoglycemic coma ) . 2 . Diabetic retinopathy , preproliferative , proliferative terminal stage ( base result oculist examination screen period 6 month prior trial ) . 3 . Diabetic nephropathy , proteinuria stage , chronic kidney disease 3 , 4 5 stage . 4 . Diabetic microangiopathy : ishemic heart disease ( medical history sudden coronary death successful reanimation , medical history miocardial infarction , stable exertional angina III IV FC ; instable angina ; postinfarction cardiosclerosis ; chronic heart failure III IV FC ) ; cerebrovascular disease ( medical history acute cerebrovascular accident ; progressive vascular leukoencephalopathy ; vascular dementia ) ; chronic obliterative peripheral vascular disease ( clinically significant ) ; diabetic neuroosteoarthropathy ; diabetic foot ( clinically significant ) . 5 . Heart rhythm disorder : IIIII atrioventricular block ; sick sinus syndrome ; long QT interval syndrome ; complete leave bundle branch block ; block 2/3 bundle branch ; WPW syndrome ; ventricular arrhythmia III grade accord LaunWolf ; paroxysmal supraventricular tachycardia ; paroxysmal/recurrent ventricular tachycardia ; atrial flutter fibrillation ; ventricular flutter fibrillation ; heart pacemaker implant . 6 . Uncontrolled arterial hypertension characterize follow blood tension value : systolic blood pressure 160 mm Hg and/or diastolic blood pressure 100 mm Hg . 7 . Severe concomitant pathology include clinically significant cardio vascular disease III IV functional class ( accord New York Heart Association classification , 1964 ) , nervous endocrine system disease , include morbid obesity ( body build index≥40.0 kg/m^2 ) , renal insufficiency , liver failure . 8 . Medical history pancreatectomy transplantation pancreatic/islet cell . 9 . Medical history renal transplantation . 10 . Malignant neoplasms/suspected malignant neoplasm . 11 . Exacerbations decompensation chronic disease affect patient 's ability participate clinical trial . 12 . The result analysis liver enzymes ( alanine aminotransferase , aspartate aminotransferase ) threefold exceed upper limit normal value . 13 . Level fast triglyceride &gt; 5.64 mmol/L . 14 . Medical history bariatric surgical operation . 15 . Medical history polyvalent allergy 16 . Allergy/ intolerance component medication use treatment . 17 . Intake medicine list section `` Prohibited concomitant treatment '' 3 month prior inclusion trial . 18 . Pregnancy , breastfeed . 19 . Drug addiction , alcohol usage amount exceed 2 unit alcohol per day . 20 . Mental disorder patient . 21 . Night work . 22 . Participation clinical trial course 3 month prior inclusion trial . 23 . Patients , investigator 's point view , fail comply observation requirement trial intake regimen investigate medicine . 24 . Other factor impede patient 's participation trial ( example , plan business trip journey ) . 25 . Patient relate research personnel investigative site , directly involve trial immediate relative researcher . The immediate relative include husband/wife , parent , child brother ( sister ) , regardless whether natural adopt . 26 . Patient work OOO `` NPF `` Materia Medica Holding '' ( i.e . company 's employee , temporary contract worker appoint official responsible carry research ) immediate relative .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Combined Treatment Patients With Type II Diabetes Mellitus</keyword>
</DOC>